Genome-wide association study of suicide attempt in a Mexican population: a study protocol

Thelma Beatriz González-Castro,1 Alma Delia Genis-Mendoza,2 Carlos Alfonso Tovilla-Zárate,3 José Jaime Martínez-Magaña,2,4 Isela Esther Juárez-Rojop,4 Emmanuel Sarmiento,5 Humberto Nicolini2

ABSTRACT

Introduction Suicidality is a complex behaviour and a major health problem; the specific features that could predispose to suicidal behaviour have been extensively investigated, most frequently in European and Asian populations. Therefore, our aim is to present a protocol that will explore suicide attempt in Mexican individuals diagnosed with psychiatric disorders, through a genome-wide association study (GWAS).

Method and analysis We will perform a GWAS by comparing 700 individuals who have suicide attempt history, with control subjects without suicide attempt history (n=500). The genotyping will be conducted using the Infinium PsychArray BeadChip and quality controls will be applied to single nucleotides (SNPs) genotyped. After that, we will perform the imputation using reference panels provided by the Haplotype Reference Consortium. We will perform two different workflows: (A) the classic GWAS analysis applying the same weight to all the variants and (B) an algorithm with prediction of deleteriousness of variants.

Ethics and dissemination This study was approved by the ethics and investigation committees of the National Institute of Genomic Medicine on 22 July 2015, No CEI 215/13. We plan to disseminate research findings in scientific conferences and as a manuscript in peer-reviewed journals.

Trial registration number CEI 215/13.

INTRODUCTION

Suicide is one of the leading causes of death worldwide. Individuals diagnosed with psychiatric disorders have higher rates of suicide compared with the general population, which emphasises a narrow relationship between suicide and psychiatric disorders. In this line of evidence, a considerable majority of suicide victims have had an undiagnosed psychiatric disorder at the time of death.1–3 Furthermore, several studies consider psychiatric disorders as one of the main risk factors of suicide. Unfortunately, up to today, the mechanisms of this relationship have not been fully disentangled.1,5

Suicidal behaviour (SB) has been defined as a complex issue that results from the combination of genetic variants along with personal experiences and environmental contribution; altogether, these factors establish the disease symptomatology manifestation.1 3 6 The results of studies based on twins, adoptions and families, support the heritability of SB, pinpointing a genetic influence.7–10 Subsequently, many candidate-gene association studies have been performed, studying the different phenotypes of SB: suicide attempts, suicide ideation and accomplished suicide.1 3 6 11 12 Unfortunately, SB is a polygenic trait and candidate-gene association studies underestimate the genetic background. In an attempt to search for this polygenic variation of SB, other strategies have been developed, such as the genome-wide association studies (GWASs).1,13,14

Over the past decade, a small number of GWASs exploring common genetic variation mostly in suicide attempters have found
significant associations between genetic components and SB, establishing possible molecular pathways involved in the susceptibility of the disease.\textsuperscript{15, 16} Although a genetic diathesis model for SB predisposition has been proposed and GWASs have suggested candidate loci or pathways, the only information available comes from studies analysing Caucasian or Asian populations, leaving behind Latin American populations including Mexicans.\textsuperscript{17–21} Therefore, more studies are necessary to have a better comprehension of the SB genetic background.

**Objectives**

Our aim is to perform the first GWAS of suicide attempters in a Mexican population, in order to explore and define the involvement of a genetic diathesis that predisposes to SB in this population. In addition, we will explore the hypothesis that there are genes and genetic variants that increase the risk of suicide attempt in the Mexican population and these factors could be common in individuals with a psychiatric diagnostic.

**METHODS AND ANALYSIS**

**Sample population and setting**

The case group (n=700) will be formed by individuals who have had at least one suicide attempt, and this will be determined using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) (SCID-I and II) in psychiatry outpatient areas from three clinical centres: ‘Dr. Gustavo A. Rovirosa’ general hospital in Tabasco, ‘Dr. Desiderio G. Carbajal’ regional hospital in Tabasco and ‘Dr. Juan N. Navarro’ psychiatric hospital in Mexico City. Individuals used as controls (n=500) will not have current or past history of any SB, will not have first degree relatives with SB history and they will be unrelated to those in the case group. Both cases and controls will be interviewed by two psychiatrist or clinical specialists, together they will determine the presence or absence of suicide attempt. All individuals will be Mexicans with Mexican ascendancy of at least two generations (Mexican parents and grandparents); they will be recruited from several hospitals and outpatient clinics in Mexico.

**Patient and public involvement**

The outcomes of the present protocol will be directly communicated to patients who participate or their legal caregivers. The results will also be discussed with their psychiatrists and the corresponding health-education structures of the clinical centres. However, the patients have not directly participated in the study design or any methodological procedures.

**Ethics and dissemination**

A written informed consent will be obtained from all individuals who accept to participate. The study will be performed in accordance with the Declaration of Helsinki (59th General Assembly, Seoul, Korea, October 2008). This study has been already approved by the ethics and investigation committees of the National Institute of Genomic Medicine (INMEGEN) on 22 July 2015, No CEI 215/13. We plan to disseminate research findings in scientific conferences and as a manuscript in peer-reviewed journals.

**Clinical assessment**

Diagnoses and clinical evaluations will be performed by at least two trained senior psychiatrists of whom at least one of them would have personally examined the patient. All participants will undergo semi-structured interviews that will include lifetime and family history of SB, among other clinical features. Suicide attempt will be defined as a self-injurious act that had at least a partial intent to end one’s life; the number of attempts, method used and medical damage of past suicide attempts will be gathered.

**Genotyping**

DNA will be isolated from peripheral blood leukocytes samples using a standardised protocol of the Genomic Wizard Purification Kit from Promega, as previously reported.\textsuperscript{22–24} The integrity of genetic material will be checked on 1% agarose gels and quantified by spectrophotometry using the NanoDrop system.

The genotyping will be performed using the Infinium PsychArray BeadChip, following the manufacturer’s protocol.\textsuperscript{25, 26} This array contains approximately 580,000 genetic variants, wherein includes a set of genetic variants previously associated with a variety of psychiatric illnesses. All genotyping analyses will be performed at the INMEGEN. For quality controls, we will filter-out samples and variants with call rates lower than 98% and variants deviating from Hardy-Weinberg equilibrium, with a $\chi^2_p$ value<1×10$^{-6}$. Gender concordance will be performed based on heterozygosity of X and Y chromosomes. All filtering processes will be done using the PLINK V.1.9 software.\textsuperscript{27} Then, we will perform a multi-dimensional scaling (MDS) analysis in PLINK, all single nucleotides (SNPs) that pass quality controls will be pruned and used to check population stratification in order to evaluate the ancestry of the individuals included. After the MDS analysis, the first five components will be used as covariates in the association analysis. MDS dimensions will be graphically represented using the ‘MDS-plot’ option. After quality control procedures, we will perform the imputation using reference panels provided by the HaploReference Consortium r.1.1; we will use the Michigan Imputation Server for the imputation.\textsuperscript{28, 29}

**Polygenic risk score calculation**

Polygenic risk score (PRS) is a measurement of genetic liability to schizophrenia, based on the Psychiatric Genomics Consortium (PGC) schizophrenia GWAS.\textsuperscript{30} SNPs will be selected and used in the PRS calculation based on p values obtained in the original PGC GWAS using PRSice.\textsuperscript{31} PRS will be performed to search for suicide attempt associations using linear regression
models adjusted by age, sex and four MDS components. The estimation of gene-based or set-based association tests using GWAS summary data will be performed using Genome-wide complex trait analysis (GCTA).

**Statistical analyses**

In order to evaluate the effect of genetic variants on SB, we will perform two workflows: (A) a classic GWAS analysis applying the same importance to all the variants and (B) algorithms for predicting deleteriousness of variants. Concerning the first workflow, we will conduct a mixed linear model analysis on imputed variants with a minor allele frequency of 5%. The implementation of linear mixed models will be performed using the GCTA software. For the second workflow, we will include the prediction of deleteriousness of variants using different prediction algorithms, such as PolyPhen, SIFT, Combined Annotation Dependent Depletion (CADD), Variant Effect Predictor (VEP) and Encyclopedia of DNA Elements (ENCODE). After the functional impact on variants prediction, we will compare cases’ allele frequency of loss-of-function, missense with deleterious effect, variants present in regulatory regions and variants with a PHRED-CADD score higher than 20, with the allele frequency of populations reported in the 1000 genomes and Exome Aggregation Consortium (ExAC) database. GWAS analysis will be performed on cases with a history of suicide attempt and compared with non-suicide attempters. Genome-wide significance will be set at \( p < 5 \times 10^{-8} \).

**Power analysis calculation**

For the GWAS analysis, we will perform power calculations using QUANTO V1.2.4 (http://biostats.usc.edu/software). This analysis uses a log-additive model of inheritance and is capable of detecting a power of 0.82 at significance threshold \( 5 \times 10^{-8} \) to detect an effect size of OR \( \geq 2.8 \) with a \( P_0 \) of 0.08 and Minor Allele Frequency (MAF) of 0.25, as observed in a previous study. The \( P_0 \) that we will use is the baseline risk of suicide attempt in our population based on previous reports. Therefore, our study will be powered to detect genetic effects.

**DISCUSSION**

Various situations and contexts have been proposed as predictors of SB; among them, the presence of a psychiatric disorder seems to be an important determinant for such behaviour. Likewise, the possible genetic predisposition to manifest SB has been supported by several investigations, but the understanding of the precise genetic system that causes such vulnerability to suicidal tendencies is still largely incomplete. Hence, the principal aim of our protocol study is to explore the potential genetic influence on SB in a Mexican population, throughout a GWAS. In addition, we want to emphasise that to the best of our knowledge, this study protocol will be the first one to evaluate SB in patients with schizophrenia and bipolar disorder in a Mexican population.

The majority of genetic epidemiology evidence suggest that SB is a complex issue, where there are multiple genes that have a small effect over SB; but if combined, could become predisposing factors. Therefore, association studies that detect small effect contributions can be more useful, which is a strength of this protocol. In this sense, one of the most powerful strengths of the GWAS is that it uses many genetic markers across the whole genome to search for associations with a particular disease; as it is based on no prior assumptions, it explores a large number of genetic variants. For these reasons, we will use GWAS’s results to explore the genetic influence on SB in schizophrenics with and without suicide attempt, bipolar patients with and without suicide attempt, suicide attempters and healthy subjects as controls. Therefore, the results of this study will provide information to better comprehend the influence of the genetic background when developing SB, among psychiatric patients.

Additionally, the findings of the present research could provide valuable information for future researchers who attempt to identify genetic risk factors of SB and help to detect and/or treat this disease. Nowadays, there are microarrays that have been used to study several genetic variables in Caucasian and Asian populations; to the best of our knowledge, however, there is no evidence reported of GWAS in studies that evaluate SB in psychiatric patients. Therefore, the outcomes of the current protocol could provide essential information. The use of this type of genetic tools will allow us to identify associated SNPs, missense and insertions and indels in mental illnesses, such as schizophrenia and bipolar disorder, as well as their possible participation as predictors of SB in a Mexican population.

In conclusion, these findings could give important information to improve the design of future chips for molecular diagnosis of psychiatric disorders in Mexicans, which will be very useful in the prevention, diagnosis and prognosis of SB in Mexico. Moreover, the findings will give a better perspective of the genetic background as a predictor of SB in psychiatric diseases. Hence, the outcomes would be useful in genetic research as well as in prevention and early diagnosis of SB in Mexicans.

**Author affiliations**

1División Académica Multidisciplinaria de Jalpa de Méndez, Universidad Juárez Autónoma de Tabasco, Jalpa de Méndez, México
2Laboratorio de Genómica de Enfermedades Psiquiátricas y Neurodegenerativas, Instituto Nacional de Medicina Genómica, Mexico, Mexico
3División Académica Multidisciplinaria de Comalcalco, Universidad Juárez Autónoma de Tabasco, Comalcalco, Mexico
4División Académica de Ciencias de la Salud, Universidad Juárez Autónoma de Tabasco, Villahermosa, Mexico
5Urgencias y Pre-consulta, Hospital Psiquiátrico Infantil Dr. Juan N. Navarro, Ciudad de México, Mexico

**Acknowledgements** The protocol study will be a doctoral thesis of TBG-C.

**Contributors** ADG-M, HN and JJM-M conceived the study, participated in its design, helped to draft the manuscript and mentored TBG-C. CAT-Z, ADG-M and JJM-M critically revised successive drafts of the manuscript and provided
important intellectual input. CAT-Z and TBB-C coordinated and supervised the integration of the manuscript. ES, IEJ-R, HN and ADG-M contributed to developing the analytic plan proposed for this study. All authors read and approved the final manuscript.

**Funding** This protocol will receive the support of INMEGEN project number 23/2015/ via HN.

**Competing interests** None declared.

**Patient consent for publication** Obtained.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc-4.0/.

**REFERENCES**


